紫杉醇脂质体联合替吉奥与XELOX在胃癌术后辅助化疗中的对比研究  

Comparative Study Between Paclitaxel Liposome Plus S-1 and XELOX as Postoperative Adjuvant Chemotherapy for Gastric Cancer

作　　者：胡泽成[1] 赵晓春[1] 伍小平[2] 樊善继 

机构地区：[1]南华大学附属第一医院肿瘤外科,湖南省衡阳市421001 [2]南华大学附属第一医院肿瘤内科,湖南省衡阳市421001

出　　处：《中国全科医学》2015年第13期1545-1548,共4页Chinese General Practice

摘　　要：目的观察紫杉醇脂质体联合替吉奥(S-1)胶囊与XELOX两种方案治疗进展期胃癌术后的效果及安全性。方法采用随机数字表法,将2009年3月—2011年1月在南华大学附属第一医院肿瘤外科行D2淋巴结清扫术,并于该院肿瘤中心进行辅助化疗的55例进展期胃癌患者分为两组,其中A组(n=29)采用紫杉醇脂质体+替吉奥方案,B组(n=26)采用XELOX方案(奥沙利铂+卡培他滨)。比较两组患者1年和3年的无复发生存期(RFS)率、总生存期(OS)率及化疗不良反应情况(包括腹泻、肝功能损害、周围神经病变、手足综合征、白细胞下降、血小板下降、血红蛋白下降、中性粒细胞下降、恶心及呕吐)。结果两组患者的1年和3年RFS率、OS率间差异均无统计学意义(P>0.05)。两组患者化疗不良反应均以骨髓抑制和恶心呕吐为主。B组手足综合征发生的强度高于A组,差异有统计学意义(P<0.05)。两组其余的不良反应强度虽有不同但差异无统计学意义(P>0.05)。结论两种方案在进展期胃癌行D2术后辅助化疗的近期疗效相当,紫杉醇脂质体联合替吉奥方案耐受性较好,具有良好的应用前景。Objective To observe the efficacy and safety of paclitaxel liposome combined with S-1 and the XELOX regimen as postoperative adjuvant chemotherapy for advanced gastric cancer. Methods A total of 55 gastric cancer patients undergoing D2 lymph node dissection and adjuvant chemotherapy in the Department of Oncological Surgery of the First Affiliated Hospital of University of South China from March 2009 to January 2011 were enrolled using random number table and were divided into group A（n=29）and group B（n=26）. Group A was administered with paclitaxel liposome combined with S-1,and group B was administered with XELOX regimen （ oxaliplatin plus capecitabine ） . The 1 - year and 3 - year recurrence free survival（RFS）,1-year and 3-year overall survival（OS）,adverse reactions（including diarrhea,liver damage,peripheral neuropathy,hand-foot syndrome,nausea and vomiting,and decrease in WBC,PLT,Hb and Neutropenia） of the two groups were observed and compared. Results No significant differences were observed in 1 -year and 3 -year RFS and OS between group A and group B（P﹥0. 05）. The primary adverse reactions were bone marrow suppression,nausea and vomiting for both groups. The incidence of hand-foot syndrome in group B was significantly higher than that in group A（P﹤0. 05）. No statistical differences were found between the two groups in terms of other side effects（P﹥0. 05）. Conclusion The paclitaxel liposome plus S-1 regimen shows a therapeutic effect similar to XELOX regimen on patients with advanced gastric cancer after D2 operation. The regimen of paclitaxel liposome plus S-1 is well tolerated and has a good application prospect.

关 键 词：胃肿瘤 放化疗 辅助 紫杉醇脂质体 替吉奥 奥沙利铂 卡培他滨 

分 类 号：R735.2[医药卫生—肿瘤]